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Original Article
Antitumor Activity of a Polypyridyl
Chelating Ligand: In Vitro and In Vivo
Inhibition of Glioma
Cle´ment N. David1, Elma S. Frias2, Catherine C. Elix2,
Kathryn E. McGovern1, Ameae M. Walker1, Jack F. Eichler2, and
Emma H. Wilson1
Abstract
Glioblastoma multiforme is an extremely aggressive and invasive form of central nervous system tumor commonly treated
with the chemotherapeutic drug Temozolomide. Unfortunately, even with treatment, the median survival time is less than 12
months. 2,9-Di-sec-butyl-1,10-phenanthroline (SBP), a phenanthroline-based ligand originally developed to deliver gold-based
anticancer drugs, has recently been shown to have significant antitumor activity in its own right. SBP is hypothesized to
initiate tumor cell death via interaction with non-DNA targets, and considering most glioblastoma drugs kill tumors through
DNA damage processes, SBP was tested as a potential novel drug candidate against glial-based tumors. In vitro studies
demonstrated that SBP significantly inhibited the growth of rodent GL-26 and C6 glioma cells, as well as human U-87,
and SW1088 glioblastomas/astrocytomas. Furthermore, using a syngeneic glioma model in mice, in vivo administration of SBP
significantly reduced tumor volume and increased survival time. There was no significant toxicity toward nontumorigenic
primary murine and human astrocytes in vitro, and limited toxicity was observed in ex vivo tissues obtained from noncancer-
ous mice. Terminal deoxynucleotidyl transferase dUTP nick end labeling staining and recovery assays suggest that SBP induces
apoptosis in gliomas. This exploratory study suggests SBP is effective in slowing the growth of tumorigenic cells in the brain
while exhibiting limited toxicity to normal cells and tissues and should therefore be further investigated for its potential in
glioblastoma treatment.
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Introduction
Glioblastoma multiforme (GBM) is an extremely aggres-
sive and invasive form of central nervous system (CNS)
tumor with a survival prognosis of less than 1 year (Stupp
et al., 2002; Hegi et al., 2004; Safdie et al., 2012; Poteet
et al., 2013). Current therapies employ surgical removal
in combination with radiation therapy and chemotherapy
(Stupp et al., 2005). Though this removes a large part of
the tumor, it often does not eliminate all tumor cells and
relapses generally occur quickly. Furthermore, current
chemotherapy and radiation therapy can leave patients
with substantial deleterious side effects (Sughrue et al.,
2009). Temozolomide (TMZ; see Scheme 1) is a che-
motherapeutic drug that has been in use since 1999 to
treat advanced glioblastomas and melanomas. Its antitu-
mor effects stem from its capability to methylate DNA at
the N-7 or O-6 position of guanine, thereby damaging the
DNA and causing cell death (Srivastava et al., 1998; Hegi
et al., 2004; Mutter and Stupp, 2006; Kim et al., 2010;
Poteet et al., 2013). Unfortunately, virtually all patients
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relapse with TMZ-resistant disease, and many patients do
not respond to TMZ (Hegi et al., 2005). The resistance to
current chemotherapies, limited success of treatment, and
poor long-term prognosis warrants the search for and
creation of new drugs, which alone or in combination
with other forms of therapy could target and eradicate
tumor cells more efficiently (Hegi et al., 2004;
Chamberlain et al., 2007).
Gold compounds have been long thought to possess
strong antitumor activity, stemming from the fact that
initial studies found some gold compounds were able to
inhibit HeLa cell growth (Thang et al., 1976).
Unfortunately, gold-based drugs were found to be
unstable in vivo and had no therapeutic advantage over
established chemotherapeutics (Thang et al., 1976; Wein
et al., 2011). However, the subsequent development of
coordinating ligands designed to stabilize gold complexes
resulted in the discovery of the anticancer activities of
gold(III) polypyridyl complexes, prompting a renewed
interest in this area of drug design (Messori et al., 2000;
Shi et al., 2006; Wein et al., 2011; Palanichamy et al.,
2012). While the development of gold(III) drugs possess-
ing polypyridyl ligand architectures has been progressing,
some reports have indicated the polypyridyl ligands
themselves exhibit antitumor activity similar to that of
the parent gold complex, suggesting that the free ligand
may play a role in the activity of this class of gold thera-
peutics. In a recent study of a gold(III) complex bearing
the 2,9-di-sec-butyl-1,10-phenanthroline (SBP; see
Scheme 1) polypyridyl ligand, control experiments
found that the free SBP ligand exhibited remarkable
in vitro activity against a variety of head-neck and lung
(A549 and H1703 lung, and 886LN, Tu212, and Tu686
head/neck) cancer lines. In particular, the study revealed
that SBP had in vitro IC50 values in the nanomolar con-
centration range, which were 20 to 100 times lower than
the commonly used chemotherapy cisplatin (See Scheme
1) and 4 to 14 times lower than the parent gold(III) com-
plex (Sanghvi et al., 2013). Thus, although metals com-
plexed to phenanthroline-based ligands continue to be
investigated for their antitumor properties (Narla et al.,
2001; Scharwitz et al., 2008; Bieda, Ott, Gust, et al.,
2009a; Bieda, Ott, Dobroschke, et al., 2009b;
Dobroschke et al., 2009; Tan et al., 2010; Komor and
Barton, 2013), our understanding of the properties and
potential chemotherapeutic action of the ligands them-
selves remains an unexplored area of research.
One important finding in regard to the antitumor effi-
cacy of SBP was that it had significant activity against the
cisplatin-resistant H1703 lung tumor cell line, suggesting
that SBP likely initiates tumor cell death via a mechanism
involving a non-DNA target (Sanghvi et al., 2013). To
date, the most successful drugs for treatment of glioblast-
oma, including TMZ, have been lipophilic alkylating
agents that disrupt tumor cell growth through processes
that initiate DNA damage (Ajaz et al., 2014). Cisplatin
and other platinum-based drugs, which initiate tumor cell
death by forming intrastrand crosslinks with DNA guan-
ine base pairs, have also been found to demonstrate
in vitro activity against glioblastoma tumors (Wolff
et al., 1999). Though platinum-based drugs have had
more limited success in vivo, novel drug delivery
approaches for glioblastoma treatment are being pursued
(Charest et al., 2013; Miura et al., 2013). Given the afore-
mentioned activity of SBP against cisplatin-resistant
tumor cells, and the fact SBP is hypothesized to have
non-DNA intracellular targets (Sanghvi et al., 2013), it
was of interest to determine if this drug might have poten-
tial as a new lead compound for glioblastoma treatment.
In particular, it was desired to determine whether a com-
pound with a potentially different mechanism of antitu-
mor activity might show promise as a therapeutic against
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Scheme 1. Molecular structure of A: 2,9-di-sec-butyl-1,10-phenanthroline (SBP); B: Cisplatin; and C: Temozolomide (TMZ).
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glioblastoma tumors. Prior to carrying out detailed mech-
anistic studies on the antitumor activity of SBP, it was
first desired to characterize the general in vitro efficacy of
this drug against a panel of glioblastoma tumor cell lines
and to determine if SBP has in vivo activity on an
implanted murine glioma brain tumor model.
In the current study, a panel of rodent and human
glioma cell lines was used for in vitro efficacy and toxicity
assays. In addition, a syngeneic mouse model that recap-
itulates several aspects of human glioblastoma was used
to investigate the antitumor capabilities of SBP in vivo.
We report that SBP has significant in vitro activity against
rodent (GL-26, C6) and human (U-87 and SW1088) glio-
blastoma/astrocytoma tumor cells and in vivo activity
against implanted murine brain tumors. Finally, we pro-
vide preliminary studies on whether SBP limits tumor cell
growth via cell cycle arrest or apoptosis.
Materials and Methods
Compound Synthesis
SBP was synthesized and purified according to previously
reported protocols (Pallenberg et al., 1995; Jakobsen and
Tilset, 2011).
Cell Lines
The murine (C57BL/6) glioma cell line, GL-26, which is
highly tumorigenic in C57BL/6 mice, was obtained as a
generous gift from Dr. Pedro Lowenstein, University of
Michigan, Ann Arbor (Candolfi et al., 2007; David et al.,
2012). GL-26 cells were cultured in Dulbecco’s modified
Eagle’s medium (DMEM)/F12 supplemented with 10%
fetal calf serum (FCS), 1% penicillin/streptomycin, 1%
L-glutamine, and 1% nonessential amino acids. Primary
murine astrocytes were purified from C57BL/6 neonate
brains and cultured in DMEM/F12 supplemented with
10% FCS, 1% nonessential amino acids, 1% L-gluta-
mine, 50 IU/ml penicillin, 50mg/ml streptomycin, and
10mM Hepes buffer. U-87 (human glioblastoma),
SW1088 (human astrocytoma), and C6 (rat glioma)
were purchased from ATCC (cat# HTB-14, HTB-12
and CCL-107) and cultured following the ATCC’s guide-
lines. Primary human astrocytes were purchased from
Sciencell (cat# HA-1800) and cultured following
Sciencell’s recommendations. Human foreskin fibroblasts
(HFFs) were cultured in DMEM/F12 supplemented with
10% FCS and 1% penicillin/streptomycin.
Growth Assay
The sulforhodamine B (SRB) cytotoxicity assays were
adapted from Skehan et al. (1990). Briefly, cells were
plated at a density of 4,000 cells/well of a 96 well plate
in a volume of 100 mL overnight at 37C and cultured in a
humidified atmosphere of 5% CO2. Cells were exposed to
SBP or TMZ at 0 to 25 mM for 48 hr before the culture
supernatant was discarded, and the cells fixed for 1 hr
with 10% cold trichloroacetic acid (100mL per well).
Cells used in recovery assay received fresh media for
48 hr following the 48 hr drug incubation before fixation.
Fixed cells were then washed five times with de-ionized
water, air dried, and stained with 0.4% SRB for 10min
(50mL per well). After washing five times in 1% acetic
acid and air-drying, bound SRB was dissolved in 10mM
unbuffered Tris base (pH 10.5; 100 mL per well). Bound
SRB was then quantified by absorbance at 492 nm on a
SpectraMax plate reader (Molecular Devices). The per-
cent survival was then calculated based upon the absorb-
ance values relative to control wells (0 mM SBP in 0.1%
dimethyl sulfoxide). All cell growth assays were done
such that each drug concentration was tested in triplicate,
and each of these independent experiments was done
three times.
Propidium Iodide
GL-26 cells were plated at 4,000 cells/well in a 96 well
plate in GL-26 media. The cells were treated 1 day post-
plating with 0 to 25 mM SBP for 48 hr. The cells were then
detached with Trypsin/EDTA (Cellgro), washed and
resuspended at 500,000 cells/ml in ice cold Naþ/Kþ
balanced phosphate-buffered saline (PBS) and fixed by
gently adding 70% ethanol and incubating for 2 hr at
4C. GL-26 cells were then resuspended in 300 to
500mL PI/Triton X-100 staining solution: 10ml of 0.
1% (v/v) Triton X-100 (Sigma) in Naþ/Kþ balanced
PBS with 2mg DNAse-free RNAse A (Sigma) and
0.40ml of 500mg/ml PI (Roche). The stain was allowed
to incubate at 37C for 15min before data acquisition on
a BD FacsCanto II flow cytometer. Independent experi-
ments were carried out where only adherent cells were
tested, as well as a combination of both adherent and
detached cells were tested. Each of these experiments
was repeated three times.
In Vivo Experiments
All animal research was performed in accordance with
the Animal Welfare Act. All protocols were approved
by the Institutional Animal Care and Use Committee
(IACUC) of the University of California, Riverside.
Female C57BL/6 mice were obtained from Jackson
Laboratories and maintained in a specific pathogen-free
environment. Mice were anesthetized with continuous
administration of 2.5% isofluorane. Cultured GL-26
cells were harvested by trypsinization, and 90,000 GL-
26 cells in 3 mL of sterile Naþ/Kþ balanced PBS were
injected intracranially. A stereotactic mouse frame was
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used to carry out the injection 1.0mm anterior and
2.0mm lateral to the junction of the coronal and sagittal
sutures (bregma), and at a depth of 2.0mm. Care was
taken to alternate injection order and group assignment
(treated vs. nontreated) to assure equal GL-26 cell viabil-
ity between the two treatment groups. SBP was adminis-
tered intravenously through the retro-orbital route at a
concentration of 10mg/kg in 200 mL sterile Naþ/Kþ
balanced PBS. Drug was administered 1, 7, and 13 days
after tumor implantation and sacrificed at Day 19 post
implantation for tumor size analysis. A separate cohort
was treated with 5mg/kg SBP every 6 days and allowed
to progress until moribund for a survival analysis
(Untreated, N¼ 5; SBP-treated, N¼ 5).
Histology
For brain tumor histology, mice were perfused intracar-
dially with 4% formaldehyde in Naþ/Kþ balanced PBS,
and brains were incubated in 4% formaldehyde overnight
followed by 30% sucrose in Naþ/Kþ balanced PBS.
Brains were flash frozen in isopentane, embedded in opti-
mal cutting temperature (OCT) compound, coronally
cryosectioned (12 mm), and stained with hematoxylin
and eosin. Another cohort of equivalently drug-treated
mice without tumors was used for liver, lung, and gut
histology. In this instance, mice were sacrificed on Day
19, and the liver, lung, and gut tissues were collected and
placed in 4% formaldehyde in Naþ/Kþ balanced PBS
overnight. The organs were then placed for 48 hr in
70% EtOH before further dehydrating, paraffin embed-
ding, and sectioning at 6 mm. Sections were then stained
with hematoxylin and eosin, and pathology was assessed
blindly and independently by a trained pathologist. A
terminal deoxynucleotidyl transferase dUTP nick end
labeling (TUNEL) staining kit was obtained from
TREVIGEN (NeuroTACS II In Situ Apoptosis
Detection Kit, Cat#4823-30-K) and used for both
ex vivo slices and in vitro staining according to manufac-
turers instructions.
Liver Toxicity
Intracardial blood was collected from the nontumor-
bearing mice, allowed to clot, and then subjected to cen-
trifugation for 10min to collect serum. Aspartate trans-
aminase (AST) and alanine transaminase (ALT) levels
were measured in the serum using Bio Scientific (3913
Todd Lane Suite 312 Austin, TX) colorimetric kits
(Cat#5605-01 and 3460-08, respectively).
Statistical Analysis
All statistical analyses were done using GraphPad Prism
software. Statistics on growth assays, tumor area, and
AST/ALT concentrations were done using an unpaired
two-tailed Student’s t test. A best-fit line was applied
to the weights of tumor-bearing treated and nontreated
mice. If the line deviates from a slope of 0, it indicates a
change in the mouse weight over the recorded time. The
survival curve was analyzed using a Mantel–Cox and a
Gehan–Breslow–Wilcoxon test using GraphPad Prism
software.
Results
SBP Inhibits Glioma Cell Growth In Vitro
To determine whether SBP had the capacity to inhibit the
growth of glioma cell lines, GL-26 and C6 cells were
cultured in vitro and incubated with concentrations of
SBP and TMZ from 0.1mM to 25 mM for 48 hr. The
drug was then removed, and the effect of SBP on cell
growth was assessed. A dose-related decrease in cell
growth between 0.8mM and 6 mM was observed in cells
treated with SBP, whereas TMZ did not affect cell viabil-
ity at any tested concentrations. At the IC50 value
observed for SBP (1.63 mM) (Figure 1(a) and (e)), GL-
26 growth was significantly reduced when compared
with GL-26 treated with TMZ (no IC50 observed;
p¼ .03) (Figure 1(a)). Similarly, at the IC50 for SBP
(0.19 mM) (Figure 1(e)), C6 cell growth was significantly
lower than in C6 cells treated with TMZ (no IC50
observed; p¼ .0112) (Figure 1(a)).
In order to assess the toxicity of the drug on normal
cells, murine primary astrocytes were treated with SBP
(0.1–25 mM) for 48 hr, and toxicity was quantified using
an SRB assay. At the observed SBP IC50 of GL-26 cells
(1.63 mM), primary murine astrocyte growth was inhib-
ited by only 14% and no cell growth inhibition was
observed at the IC50 of C6 cells (0.19 mM) treated with
SBP (Figure 1(b)). This suggests that SBP has a thera-
peutic window of between 0.19 mM and 1.63 mM for the
murine cells tested.
In an effort to assess the translational efficacy of SBP,
the drug was tested against two human glioma lines. U-87
(human glioblastoma) and SW1088 (human astrocytoma)
cells were incubated with the same concentration regime
of SBP described above. At the IC50 of U-87 treated with
SBP (3.04 mM) (Figure 1(e)), glioma growth is signifi-
cantly reduced when compared with U-87 treated with
TMZ (no IC50 observed; p¼ .0102) (Figure 1(c)). At the
IC50 of SW1088 cells treated with SBP (0.33 mM) (Figure
1(e)), cell growth is significantly lower than in SW1088
cells treated with TMZ (no IC50 observed; p¼ .0005)
(Figure 1(c)). To determine whether there was any tox-
icity of SBP on noncancerous human cells, primary
human astrocytes and HFFs were treated with SBP. At
the IC50 of SW1088 cells (0.33 mM) (Figure 1(e)), HFF
cell growth and primary human astrocyte growth were
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(a) (b)
(c)
(e)
(f)
(d)
Figure 1. In vitro GL-26 inhibition with SBP: GL-26 and C6 cells were grown in a 96 well plate and treated with SBP or TMZ at 0.1 to
25 mM (a). To test SBP toxicity on nontumor cells, primary murine astrocytes were plated and treated as above (b). U-87 and SW1088 cells
were grown in a 96 well plate and treated with SBP or TMZ at 0.1 to 25mM (c). To test SBP toxicity on nontumor cells, primary human
astrocytes and human foreskin fibroblasts (HFF) were plated and treated as above (d). IC50 (mM) displayed for each cell line tested (e). The
largest toxicity window between normal and glioma cells plotted for both murine and human cells. (Student’s t test, primary murine
astrocytes vs. GL-26 and C6 p< .0001; primary human astrocytes and HFF vs. SW1088 p¼ .0006 and p¼ .0007 respectively) (f). The
sulforhodamine B (SRB) colorimetric assay was used to measure and plot fraction of growth of treated wells compared with nontreated
controls. All cell growth assays were done in a minimum of triplicates and repeated a minimum of nine times. SBP ¼ 2,9-Di-sec-butyl-1,10-
phenanthroline; TMZ ¼ Temozolomide.
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unaffected (Figure 1(d)). This suggests the therapeutic
window for SBP in human cells is between 0.33mM and
3.04mM.
In total, these results suggest SBP is significantly more
effective at inhibiting the growth of these specific mouse
and human tumor cells than the currently used glioma
chemotherapy, TMZ. The concentration of SBP with
the greatest efficacy against tumor cells and least toxicity
in normal astrocytes was 3.2 mM for rodent cells and
0.4 mM for human cells (Figure 1(f)) in vitro.
SBP Induces GL-26 Apoptosis
An important consideration is whether chemotherapeu-
tics kill off and remove cancer cells or simply inhibit their
growth. If cell growth is inhibited by the drug, continuous
treatment is required to prevent regrowth. Therefore, pre-
liminary studies were carried out in an effort to determine
whether SBP induces tumor cell death or whether the
drug simply disrupts cell growth. First, to test whether
constant SBP administration is necessary to maintain
growth inhibition, an SRB recovery assay was performed.
Allowing the glioma cells to recover for 48 hr in fresh
medium did not rescue cell growth. Instead significantly
greater cell death was observed in the recovered versus
acutely treated cells (p¼ .002) (Figure 2(a)). These data
demonstrate that GL-26 cells continue dying after the
removal of SBP and suggested that SBP targeted and
disrupted cell survival rather than cell proliferation
mechanisms.
To assess the effects of SBP on cell proliferation versus
apoptosis, cell cycle analysis was performed using propi-
dium iodide. Figure 2(b) demonstrates that SBP-treated
cells were still capable of advancing to the S, G2, and
mitotic phases and were thus not arrested in the G1
phase. However, the proportion of cells in these phases
was reduced and treated cells had a significantly larger
population of dead cells compared with untreated con-
trols. To confirmwhether cell death was the result of apop-
tosis, culturedGL-26 cells treated with SBPwere subjected
(a) (b)
(c)
Figure 2. The compound SBP induces apoptosis: GL-26 cells were grown in a 96 well plate and treated with 0.4 to 25 mM SBP. After 48 hr
incubation, the drug was removed and cells cultured for an additional 48 hr in fresh media. SRB was used to measure and plot fraction of
growth of treated wells compared with a nontreated control. Nonrecovered GL-26 cells are plotted for reference (a). Propidium iodide
staining intensity was measured by flow cytometry and plotted versus cell number to identify cell cycle stages (S: Synthesis; M: Mitotic) (b).
SBP-treated and untreated cultured GL-26 cells were stained for apoptosis (TUNEL). The positive control was treated with the kit’s
nuclease to generate DNA breaks in every cell (c). Both recovery and propidium iodide experiments were independently repeated a
minimum of three times. SBP ¼ 2,9-Di-sec-butyl-1,10-phenanthroline; SRB ¼ sulforhodamine B; TUNEL ¼ terminal deoxynucleotidyl
transferase dUTP nick end labeling.
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to TUNEL staining (Figure 2(c)). No positive staining was
detected in the untreated sample, suggesting that no apop-
tosis occurred during the culturing of GL-26 cells in media
alone (Figure 2(c)). The nuclease-treated positive control
was uniformly TUNEL positive, and the dark staining in
the SBP-treated GL-26 cells indicates that these cells are
also undergoing apoptosis. These results demonstrate that
SBP does not affect cell cycle progression, but rather kills
GL-26 cells by inducing apoptosis.
SBP Inhibits In Vivo Glioma Growth
Although no mouse model accurately mimics the gener-
ation of human GBM, intracranial injection of the GL-26
cell line leads to a morphologically similar and syngeneic
tumor. It is also highly aggressive and invasive making it
a valuable test for potential therapeutics. The tumors are
extremely proliferative, and mice routinely die within
30 days following intracranial injection. This type of
tumor implantation has been shown to lead to a robust
tumor within a week (Candolfi et al., 2007; David et al.,
2012; Safdie et al., 2012). After implanting the tumors,
treatment mice were treated intravenously with SBP, and
control mice were treated intravenously with saline solu-
tion on 1, 7, and 13 days post GL-26 cell injection.
All treatment and control mice were sacrificed at Day
19, and serial brain sections were stained with hematoxy-
lin and eosin to reveal general morphology. In untreated
mice, tumors were extensive. Glioma growth expanded
from the striatum to most of the cortex of the injected
hemisphere (Figure 3(a)). In contrast, mice treated with
SBP had markedly smaller tumors (Figure 3(b)). Indeed,
tumors in the SBP group were largely restricted to areas
directly adjacent to the needle tract, and constrained to
small areas of the striatum, although sometimes they
expanded minimally to the cortex. In some cases, the
untreated tumors expanded to the contralateral hemi-
sphere, whereas the treated tumors never penetrated
this region (Figure 3(a)). For each animal, tumor size
was quantified by pixel area starting at the largest
tumor cross-section (position 0) and measuring the
tumor area in 100 mm intervals (rostral and caudal).
Untreated animals were found to possess significantly
larger tumors than the SBP-treated group (Not treated:
48187 7736, SBP treated: 5489 1369, p¼ .0056, mea-
sured at the largest tumor cross-section) (Figure 3(b)).
Body weights were recorded for 19 days after
tumor implantation, and as expected, a decrease in
weight was observed in both treated and nontreated
groups during the first week post tumor implantation
(Figure 3(c); Safdie et al., 2012). However, whereas
mice treated with SBP regained nearly all their initial
weight (>98%), mice left untreated exhibited continued
weight loss (Figure 3(c)). A best-fit line (not shown)
revealed that the nontreated group significantly deviated
from zero (p¼ .0261), whereas the SBP-treated mice
weights did not (p¼ .8792).
The in vitro assays demonstrated that SBP inhibited
GL-26 cell growth via the induction of apoptosis. To
determine whether apoptosis of GL-26 cells was a poten-
tial cause of the reduced tumor size in vivo, in situ
TUNEL staining was conducted on serial brain sections
from treated and untreated mice (Figure 3(d)). The
untreated tumor displays faint positive TUNEL stain
consistent with tumor growth and destruction of
normal tissue (Kim et al., 2010). In contrast, SBP-treated
tumors revealed dark brown cytoplasmic and nuclear
staining indicative of cell necrosis and increased DNA
fragmentation, respectively (Figure 3(d)). These data are
consistent with SBP causing cell death via apoptosis as
seen in vitro.
To test whether decreased tumor size and increased
tumor cell apoptosis translates to an increase in survival
time, mice were allowed to progress to moribund state
and survival monitored. Mice treated with SBP survived
significantly longer than untreated mice (Mantel–Cox test
p¼ .0384; and Gehan–Breslow–Wilcoxon test p¼ .0472)
with untreated mice living a median of 35 days and SBP-
treated mice living a median of 46 days (Figure 3(e)). In
combination with the ex vivo TUNEL, these data suggest
that SBP treatment slows tumor growth, likely via apop-
tosis, and leads to improved survival.
SBP Does not Cause Overt Peripheral Pathology
Even though minimal inhibition of primary astrocytes
was observed in both murine and human cells, in vivo
administration can cause accumulation and breakdown
products not observed in vitro. To determine the in vivo
toxicity of SBP, nontumor-bearing mice were treated with
either saline or 10mg/kg SBP. After administering these
treatments on Days 1, 7, and 13, the same regime for
tumor inhibition, both the untreated control mice and
SBP-treated mice were euthanized on Day 19. The liver,
lungs, and proximal small intestines were subsequently
collected for histopathological analysis. In the duode-
num, no general pathology that might have resulted
from inhibition of cell division was detected, as there
were no differences in crypt or villus architecture, or
goblet cell density between treated and untreated mice.
Analysis of lung tissue also revealed no overt pathology.
Treated liver sections revealed minor endothelial damage,
but no overt hepatocyte damage (Figure 4(a)). Serum
concentrations of liver enzymes were also measured to
provide an indication of potential toxicity (Danan and
Benichou, 1993; Amacher, 1998). Neither AST nor
ALT concentrations, early indicators of toxicity caused
by an intravenously administrated drug (Danan and
Benichou, 1993; Scheig, 1996; Amacher, 1998), were sig-
nificantly different between treated and nontreated mice
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(a) (b)
(c)
(d)
(e)
Figure 3. SBP inhibits in vivo glioma growth: Hematoxylin and eosin stained ex vivo coronal slices were taken from SBP-treated mice and
nontreated mice (N¼ 3 for each group) (a) and tumor section areas quantified (Student’s t test, nontreated: 48187 7736, SBP treated:
5489 1369 p¼ .0056). T¼ tumor (b). Tumor-bearing mice were treated on Days 1, 7, and 13 post injection and sacrificed on Day 19.
Mouse weights were recorded during the 19-day trial. A best-fit line (not shown) reveals a significant weight decrease in nontreated animals
(p¼ .0261) but not in SBP-treated animals (p¼ .8792) (c). Ex vivo slices were stained for apoptosis (TUNEL) in SBP-treated (middle panel)
and nontreated mice (right panel). Positive control was treated with the kit’s nuclease to generate DNA breaks in every cell (left panel) (d).
For all experiments above, N¼ 4 for both treated and nontreated mice. GL-26 implanted mice were either left untreated (N¼ 5) or
treated every 6 days with 10mg/kg SBP (N¼ 5) and allowed to progress to moribund. A Mantel–Cox test p¼ .0384; and Gehan–Breslow–
Wilcoxon test p¼ .0472 were used to test significance (e). SBP¼ 2,9-Di-sec-butyl-1,10-phenanthroline; TUNEL ¼ terminal deoxynu-
cleotidyl transferase dUTP nick end labeling.
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(Figure 4(b)). These results reveal that SBP results in neg-
ligible in vivo toxicity when 10mg/kg SBP is administered
to mice over a 19-day period.
Discussion
With current combination therapies extending the sur-
vival rate of patients with gliomas by a mean of 8 to 18
months (Chamberlain et al., 2007; Poteet et al., 2013),
more potent compounds are desperately needed to con-
trol tumor growth. In this study, we used the GL-26 cell
line as a model for glioblastoma. The GL-26 cells exhibit
similar aggressive, proliferative, and tumorigenic proper-
ties as gliomas seen in humans and express the mouse
version of CD133, associated with tumor stem cells
(Candolfi et al., 2007; Golebiewska et al., 2013).
Although implantation of GL-26 cells has limitations
compared with a xenotransplant that enables in vivo test-
ing on human tumor cells or a genetic model that enables
the evaluation of cancer-initiating events (Chen et al.,
2012), these cells, when injected into the mouse striatum
establish a large and rapidly growing tumor that is mor-
phologically similar to GBM (Stupp et al., 2002; Candolfi
et al., 2007; Smith et al., 2009; Sughrue et al., 2009; David
et al., 2012; Golebiewska et al., 2013). It also allows ana-
lysis in an immunologically intact animal where the
tumor is tolerated in the murine brain. The resulting
highly invasive tumor makes it a strong and therefore
valuable test for potential therapies (Candolfi et al.,
2007; Smith et al., 2009; Safdie et al., 2012).
Previously, SBP was found to have remarkable in vitro
activity against a panel of three head-neck and two lung
(a)
(b)
Figure 4. SBP does not cause peripheral pathology: Sections (6 mm), from liver, lung, and gut were obtained from SBP-treated and
nontreated mice, stained with hematoxylin and eosin, and assessed blindly by a trained pathologist (a) (N¼ 4 for both treated and
nontreated mice). Blood samples from treated and untreated mice were tested for levels of alanine aminotransferase and aspartate
aminotransferase (Student’s t test, ALT: p¼ .2596 and AST p¼ .3982) (b) (N¼ 4 for both treated and nontreated mice). SBP¼ 2,9-Di-sec-
butyl-1,10-phenanthroline.
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tumor lines, and when tested against a cisplatin-resistant
tumor was found to have an IC50 value approximately
100 times lower than cisplatin (Sanghvi et al., 2013). The
prime mechanism of cisplatin is thought to be intercal-
ation of DNA (Komor and Barton, 2013). Such a signifi-
cant reduction in IC50 by SBP could therefore point to a
novel mechanism not dependent on DNA interactions.
Glioma treatment is notoriously difficult, and the limita-
tions are often due to tumor resistance to typical DNA
targeting antiglioma drugs. Thus, we sought to test the
in vitro anticancer activity of SBP against the rodent C6
and GL-26, and the human U-87 and SW1088 cell lines
and compare it with the clinically used glioblastoma drug
TMZ. Even though previous reports have shown the
in vitro activity of polypyridyl ligands (Thang et al.,
1976; Chamberlain et al., 2007; Roy et al., 2008;
Wesselinova et al., 2009; Wein et al., 2011; Palanichamy
et al., 2012), this report is to our knowledge the first study
on the in vitro and in vivo anticancer activity of this class
of compounds against glioblastoma tumors. The data
reported here demonstrate strong in vitro toxicity of
SBP against glioma cell lines at low micromolar concen-
trations, with significantly diminished toxicity to both
noncancerous human fibroblasts and noncancerous pri-
mary human and murine astrocytes. In addition, we dem-
onstrate that intravenously administered SBP can
significantly reduce the growth of an intracranially
implanted murine brain tumor resulting in an increase
in survival similar to the TMZ murine glioma model
(Kim et al., 2010).
A major concern in new drug development is the side
effects associated with the drug. We have demonstrated
high levels of cytotoxicity against GL-26, C6, and
SW1088 at low micromolar concentrations, with minimal
toxicity toward primarymurine and human astrocytes and
the noncancerous HFF cell line. AST and ALT are often
used as markers for liver health during chemotherapy,
where elevated levels indicate liver damage and the AST/
ALT ratio can further be used to differentiate between the
causes of liver damage (Danan and Benichou, 1993;
Scheig, 1996; Amacher, 1998). Following treatment with
SBP, AST, and ALT levels were similar to untreated mice
and fell well within their respective normal physiological
ranges. Furthermore, histopathalogical analysis of the
proximal gut, lung, and liver only revealed minor
damage to liver endothelial cells. These results mirror
the low toxicity observed in TMZ-treated patients
(Friedman et al., 2000; Su et al., 2004; Pouratian et al.,
2007; Niewald et al., 2011). Perhaps more importantly,
SBP treatment resulted in smaller, more contained
tumors. This is especially relevant, as contained tumors
are easier to remove surgically (Duffau, 2009). Thus, the
route of administration, the strong antitumor properties,
and the low toxicity to normal cells suggest SBP has poten-
tial for future anticancer development.
Even though in vivo experiments corroborated the
in vitro data that demonstrated increased apoptosis in
SBP-treated groups compared with nontreated controls,
the obvious question remains: What is the mechanism by
which SBP induces apoptosis? More specifically, is SBP-
induced apoptosis a result of a similar mechanism as
TMZ, which is thought to methylate guanine residues
in the DNA (Srivastava et al., 1998; Hegi et al., 2004;
Mutter and Stupp, 2006; Chamberlain et al., 2007; Kim
et al., 2010; Poteet et al., 2013)? At first glance, it might be
expected that SBP acts as a DNA intercalator, as the
compound has significant aromatic character. This class
of compounds is known to have significant interactions
with DNA, which can result in disruption of DNA rep-
lication and induction of cell death in a similar fashion to
the commonly used chemotherapy cisplatin (Kelland,
2006). However, as previously stated, SBP has enhanced
antiproliferative effects on cisplatin-resistant cell lines.
This suggests that the drug likely initiates tumor cell
death via a mechanism not related to DNA interactions
(Sanghvi et al., 2013). Additionally, the fact that TMZ
exhibits no inhibition of tumor cell growth at any of the
concentrations tested for SBP further corroborates the
notion that SBP likely has a distinct DNA-independent
mechanism. All of the tumor cell lines used in this study
were desensitized to TMZ, a known DNA methylating
agent, whereas all of the tumor cell lines were sensitive to
SBP further suggesting that SBP acts differently than
TMZ to inhibit growth. Finally, SBP has significantly
reduced cytotoxicity toward noncancerous cells.
Because DNA repair mechanisms are more vital to
tumor cell proliferation compared with normal cell div-
ision, the observation that SBP has significantly stronger
antiproliferative activity against tumor cell lines versus
normal cells could point to SBP targeting enzymes
involved in DNA repair. A report from Mendes et al.
(2011) describes the poly(ADP-ribose) polymerase-1
(PARP-1) inhibition of gold(III) complexes possessing
phenanthroline ligands that are in the same family as
SBP. The gold(III) complex bearing the unsubstituted
1,10-phenanthroline was found in particular to be a
potent PARP-1 inhibitor, involved in DNA repair mech-
anisms, and the authors attribute the gold complex’s
activity to binding with the zinc finger motif in the
enzyme. Given that SBP can act as a potent metal chela-
tor, inhibition of DNA repair via binding to the zinc
finger domain of PARP-1 is a plausible antitumor mech-
anism for this drug. Future research efforts in our lab will
focus on testing this hypothesis.
In this report, the antitumor activity of SBP on glio-
blastomas was tested both in vitro and in vivo. The data
demonstrate the potent antitumor activity of SBP in vitro
with minimal toxicity to normal cells. The antitumor
activity of SBP does not appear to be mediated by cell
cycle disruption, but rather by inducing cell death as
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demonstrated by propidium iodide and TUNEL staining.
SBP also reduced tumor size in an intracranial murine
brain tumor without causing apparent pathology to
normal tissues. Finally, SBP significantly increased sur-
vival time of mice intracranially injected with the GL-26
cell lines. Though further research should focus on the
capability of SBP to stop or eradicate well-established
tumors and the mechanism of action, the results
described here clearly demonstrate that SBP has signifi-
cant antiglioma activity, making it an important chemo-
therapy candidate for this aggressive, invasive, and
difficult-to-treat class of tumor.
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